Nasdaq1mon
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
ONAPGO, a subcutaneous infusion device, treats motor fluctuations ... improving the consistency of symptom control. ONAPGO is set to be available in the U.S. by the second quarter of 2025 ...
Medscape2y
Long-Acting, Subcutaneous Levodopa In Parkinson's Disease: Is It Safe?
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Source of the Spring4y
Report: United Therapeutics Launches First Product of 2021 After Pandemic-Related Delays
“Remunity is a small, discreet pump that delivers Remodulin in prefilled cassettes that are delivered directly to patients, offering significant improvements over current subcutaneous pumps.” “The ...